Alzheimer's disease. It is not known whether ␤-amyloid is the cause of impairment of energy metabolism, nor whether impaired energy metabolism is specific to neurons. Our results, using primary neuronal cultures, show that 24-h incubation with A␤ 25-35 caused a generalized decrease in the specific activity of mitochondrial enzymes per milligram of cellular protein, induced mitochondrial swelling, and decreased total mitochondrial number. Incubation with A␤ 25-35 decreased ATP concentration to 58% of control in neurons and 71% of control in astrocytes. Levels of reduced glutathione were also lowered by A␤ 25-35 in both neurons (from 5.1 to 2.9 nmol/mg protein) and astrocytes (from 25.2 to 14.9 nmol/mg protein). We conclude that 24-h treatment with extracellular A␤ 25-35 causes mitochondrial dysfunction in both astrocytes and neurons, the latter being more seriously affected. In astrocytes mitochondrial impairment was confined to complex I inhibition, whereas in neurons a generalized loss of mitochondria was seen. © 2002 Elsevier Science (USA)
INTRODUCTION
Alzheimer's disease (AD) is characterized by the accumulation of neurofibrillary tangles and neuritic plaques in the brain. The plaques contain a dense core of ␤-amyloid (A␤), surrounded by dystrophic neurites and activated glial cells. A substantial deficit of energy metabolism is also a feature of AD. Impaired glucose metabolism, independent of brain atrophy, has been identified using brain imaging techniques (Ibanez et al., 1998) . There is evidence for a profound deficit of mitochondrial metabolism including reduced activity of the enzyme complexes cytochrome oxidase (Kish et al., 1992; Mutisya et al., 1994; Parker, Jr. et al., 1994) , pyruvate dehydrogenase (PDHC) (Sorbi et al., 1983) , and ␣-ketoglutarate dehydrogenase (␣-KGDHC) (Butterworth and Besnard, 1990; Mastrogiacoma et al., 1996) . In addition, recent studies have provided evidence of a specific loss of functional mitochondria in affected brain regions of AD patients (de la Monte et al., 2000; Hirai et al., 2001) .
The role of A␤ in the disruption of energy metabolism observed in AD brain is not well-defined. Cytotoxic concentrations of A␤ have consistently been shown to inhibit the chemical reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in a variety of cultured cell types. Although this could possibly be interpreted as evidence for A␤-induced mitochondrial impairment, this conclusion has been called into question by Liu and colleagues (Liu and Schubert, 1997) , who showed that A␤ inhibits MTT reduction by enhancing MTT formazan exocytosis, not by inhibiting mitochondrial redox activity. 
